Eagle Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
134
- Stock Symbol
-
EGRX
- Investments
-
5
- Share Price
-
$0.90
- (As of Friday Closing)
Eagle Pharmaceuticals General Information
Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
Contact Information
Website
www.eagleus.comCorporate Office
- 50 Tice Boulevard
- Suite 315
- Woodcliff Lake, NJ 07677
- United States
Corporate Office
- 50 Tice Boulevard
- Suite 315
- Woodcliff Lake, NJ 07677
- United States
Eagle Pharmaceuticals Stock Performance
As of 13-Nov-2026, Eagle Pharmaceuticals’s stock price is $0.90. Its current market cap is $11.8M.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.90 | $0.82 | $11.8M | 3.98K |
Eagle Pharmaceuticals Financials Summary
As of 30-Jun-2023, Eagle Pharmaceuticals has a trailing 12-month revenue of $258M.
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 310,515 | 429,843 | 589,570 | 556,111 |
| Revenue | 257,551 | 316,610 | 171,546 | 187,802 |
| EBITDA | 55,603 | 77,231 | 287 | 28,230 |
| Net Income | 11,948 | 35,642 | (8,627) | 11,989 |
| Total Assets | 404,822 | 406,160 | 253,732 | 253,190 |
| Total Debt | 71,615 | 64,000 | 26,916 | 34,258 |
Eagle Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eagle Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Eagle Pharmaceuticals Comparisons
Industry
Financing
Details
Eagle Pharmaceuticals Competitors (24)
One of Eagle Pharmaceuticals’s 24 competitors is Merck, a Corporation company based in Darmstadt, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck | Corporation | Darmstadt, Germany | ||||
| Nymox Pharmaceutical | Corporation | Saint Laurent, Canada | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Vicore Pharma Holding | Formerly VC-backed | Stockholm, Sweden |
Eagle Pharmaceuticals Patents
Eagle Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024326051-A1 | Use of remimazolam for pediatric sedation | Pending | 11-Aug-2023 | ||
| EP-4757802-A2 | Use of remimazolam for pediatric sedation | Pending | 11-Aug-2023 | ||
| WO-2025038446-A2 | Use of remimazolam for pediatric sedation | Inactive | 11-Aug-2023 | ||
| WO-2025038446-A3 | Use of remimazolam for pediatric sedation | Inactive | 11-Aug-2023 | ||
| JP-2026015586-A | Pemetrexed formulation | Pending | 05-Oct-2020 |
Eagle Pharmaceuticals Signals
Eagle Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eagle Pharmaceuticals Investments & Acquisitions (5)
Eagle Pharmaceuticals’s most recent deal was a Early Stage VC with Enalare for . The deal was made on 09-Aug-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Enalare | 09-Aug-2022 | Early Stage VC | Drug Discovery | ||
| Acacia Pharma | 09-Jun-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Tyme Technologies | 07-Jan-2020 | PIPE | Biotechnology | ||
| Arsia Therapeutics | 16-Nov-2016 | Merger/Acquisition | Drug Delivery | ||
| Karalex Pharma | 31-Dec-2008 | Merger/Acquisition | Pharmaceuticals |
Eagle Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
28.04 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Biotechnology
Subindustry
of 444
Rank
Percentile
Eagle Pharmaceuticals Exits (2)
Eagle Pharmaceuticals’s most recent exit was on 07-Jan-2020 from Tyme Technologies. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Tyme Technologies | 07-Jan-2020 | Completed |
|
||
| Karalex Pharma | 31-Dec-2008 | Merger/Acquisition | Completed |
Eagle Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Acacia Pharma | Cambridge, United Kingdom | 2007 |
Eagle Pharmaceuticals FAQs
-
When was Eagle Pharmaceuticals founded?
Eagle Pharmaceuticals was founded in 2007.
-
Where is Eagle Pharmaceuticals headquartered?
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, NJ.
-
What is the size of Eagle Pharmaceuticals?
Eagle Pharmaceuticals has 134 total employees.
-
What industry is Eagle Pharmaceuticals in?
Eagle Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Eagle Pharmaceuticals a private or public company?
Eagle Pharmaceuticals is a Public company.
-
What is Eagle Pharmaceuticals’s stock symbol?
The ticker symbol for Eagle Pharmaceuticals is EGRX.
-
What is the current stock price of Eagle Pharmaceuticals?
As of 13-Nov-2026 the stock price of Eagle Pharmaceuticals is $0.90.
-
What is the current market cap of Eagle Pharmaceuticals?
The current market capitalization of Eagle Pharmaceuticals is $11.8M.
-
What is Eagle Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Eagle Pharmaceuticals is $258M.
-
Who are Eagle Pharmaceuticals’s competitors?
Merck, Nymox Pharmaceutical, Biocon, Cipla, and Vicore Pharma Holding are some of the 24 competitors of Eagle Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process